Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


30.05.2022

1 ACS Appl Bio Mater
1 ACS Sens
1 Aging (Albany NY)
1 Am J Health Syst Pharm
1 Am Soc Clin Oncol Educ Book
1 Ann Diagn Pathol
1 Biochem Biophys Res Commun
1 BMC Urol
1 BMJ Case Rep
2 Cancer Sci
1 Carcinogenesis
2 Cell Death Dis
1 Comput Intell Neurosci
2 Crit Rev Oncol Hematol
1 Eur Urol
1 Front Genet
1 Front Immunol
1 Front Oncol
2 Future Oncol
2 Int Braz J Urol
1 Int J Mol Med
3 Int J Urol
1 Int Urol Nephrol
1 J Control Release
1 J Oncol
1 Math Biosci Eng
1 Medicine (Baltimore)
6 Minerva Urol Nephrol
1 Neuro Endocrinol Lett
2 Prog Urol
1 Scand J Urol
1 Sci Rep
1 Spectrochim Acta A Mol Biomol Spectrosc
1 Toxicol Pathol
1 Urol Oncol
1 Vet Med Sci


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    ACS Appl Bio Mater

  1. LIAO MY, Huang TC, Chin YC, Cheng TY, et al
    Surfactant-Free Green Synthesis of Au@Chlorophyll Nanorods for NIR PDT-Elicited CDT in Bladder Cancer Therapy.
    ACS Appl Bio Mater. 2022 May 26. doi: 10.1021/acsabm.2c00228.
    PubMed         Abstract available


    ACS Sens

  2. JIAN Y, Zhang N, Liu T, Zhu Y, et al
    Artificially Intelligent Olfaction for Fast and Noninvasive Diagnosis of Bladder Cancer from Urine.
    ACS Sens. 2022 May 25. doi: 10.1021/acssensors.2c00467.
    PubMed         Abstract available


    Aging (Albany NY)

  3. LI M, Xu DM, Lin SB, Yang ZL, et al
    Transcriptional expressions of hsa-mir-183 predicted target genes as independent indicators for prognosis in bladder urothelial carcinoma.
    Aging (Albany NY). 2022;14:3782-3800.
    PubMed         Abstract available


    Am J Health Syst Pharm

  4. SIEFKER-RADTKE AO, Loriot Y
    Erdafitinib for locally advanced or metastatic urothelial carcinoma.
    Am J Health Syst Pharm. 2022;79:824-825.
    PubMed        


    Am Soc Clin Oncol Educ Book

  5. APOLO AB, Msaouel P, Niglio S, Simon N, et al
    Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers.
    Am Soc Clin Oncol Educ Book. 2022;42:1-16.
    PubMed         Abstract available


    Ann Diagn Pathol

  6. KRISHNAMURTHY K, Rosen S, Ye H, Sun Y, et al
    Yolk sac differentiation in urothelial carcinoma - A rare variant originating from aberrant differentiation of sarcomatoid components.
    Ann Diagn Pathol. 2022;58:151923.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  7. CAO X, Yu S, Wang W, Sun R, et al
    Lamprey immunity protein enables detection for bladder cancer through recognizing N-hydroxyacetylneuraminic acid (Neu5Gc)-modified as a diagnostic marker and exploration of its production mechanism.
    Biochem Biophys Res Commun. 2022;614:153-160.
    PubMed         Abstract available


    BMC Urol

  8. SHEN Z, Xue D, Wang K, Zhang F, et al
    Metformin exerts an antitumor effect by inhibiting bladder cancer cell migration and growth, and promoting apoptosis through the PI3K/AKT/mTOR pathway.
    BMC Urol. 2022;22:79.
    PubMed         Abstract available


    BMJ Case Rep

  9. TOOHEY TP, Wallace S, Toohey MG, Francis IC, et al
    Papillitis and uveitis complicating Bacillus Calmette-Guerin immunotherapy.
    BMJ Case Rep. 2022;15.
    PubMed         Abstract available


    Cancer Sci

  10. NAKANO K, Koh Y, Yamamichi G, Yumiba S, et al
    Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma.
    Cancer Sci. 2022;113:1830-1842.
    PubMed         Abstract available

  11. IGAMI K, Uchiumi T, Shiota M, Ueda S, et al
    Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients.
    Cancer Sci. 2022 May 24. doi: 10.1111/cas.15438.
    PubMed         Abstract available


    Carcinogenesis

  12. ZHANG X, Tang X, Pan L, Li Y, et al
    Elevated lncRNA-UCA1 upregulates EZH2 to promote inflammatory response in sepsis-induced pneumonia via inhibiting HOXA1.
    Carcinogenesis. 2022;43:371-381.
    PubMed         Abstract available


    Cell Death Dis

  13. XIAO D, Hu X, Peng M, Deng J, et al
    Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy.
    Cell Death Dis. 2022;13:499.
    PubMed         Abstract available

  14. ZHOU Z, Xiong L, Wu Z, Jiang L, et al
    Nkx2.8 promotes chemosensitivity in bladder urothelial carcinoma via transcriptional repression of MDR1.
    Cell Death Dis. 2022;13:492.
    PubMed         Abstract available


    Comput Intell Neurosci

  15. ZHENG P, Zhang J, Zhu Y, Guan X, et al
    Comparative Analysis of the Efficacy of Transurethral Bipolar Plasma Needle Electrode and Ring Electrode in the Treatment of Non-Muscle-Invasive Bladder Cancer.
    Comput Intell Neurosci. 2022;2022:6044676.
    PubMed         Abstract available


    Crit Rev Oncol Hematol

  16. AUDISIO M, Tucci M, Di Stefano RF, Parlagreco E, et al
    New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine?
    Crit Rev Oncol Hematol. 2022;174:103682.
    PubMed         Abstract available

  17. BELLMUNT J, Valderrama BP, Puente J, Grande E, et al
    Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management.
    Crit Rev Oncol Hematol. 2022;174:103683.
    PubMed         Abstract available


    Eur Urol

  18. RADZISZEWSKI P, Szablonski W
    Re: Bladder Cancer in Patients Younger than 40 Years: Outcomes from the National Cancer Database de la Calle CM, Washington SL 3rd, Lonergan PE, et al World J Urol 2021;39:1911-6.
    Eur Urol. 2022 May 19. pii: S0302-2838(22)01812.
    PubMed        


    Front Genet

  19. LIANG S, Fang K, Li S, Liu D, et al
    Immune Microenvironment Terms Signature Robustly Predicts the Prognosis and Immunotherapy Response in Bladder Cancer Based on Large Population Cohorts.
    Front Genet. 2022;13:872441.
    PubMed         Abstract available


    Front Immunol

  20. LIU C, He D, Zhang S, Chen H, et al
    Homogeneous Polyporus Polysaccharide Inhibit Bladder Cancer by Resetting Tumor-Associated Macrophages Toward M1 Through NF-kappaB/NLRP3 Signaling.
    Front Immunol. 2022;13:839460.
    PubMed         Abstract available


    Front Oncol

  21. CHEN K, Zhu S, Yu W, Xia Y, et al
    Corrigendum: Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
    Front Oncol. 2022;12:908832.
    PubMed         Abstract available


    Future Oncol

  22. POWLES T, Park SH, Voog E, Caserta C, et al
    Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
    Future Oncol. 2022;18:2361-2371.
    PubMed         Abstract available

  23. FRANZA A, Pirovano M, Giannatempo P, Cosmai L, et al
    Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations.
    Future Oncol. 2022;18:2455-2464.
    PubMed         Abstract available


    Int Braz J Urol

  24. NICOLA R, Pecoraro M, Lucciola S, Dos Reis RB, et al
    VI-RADS score system - A primer for urologists.
    Int Braz J Urol. 2022;48:609-622.
    PubMed         Abstract available

  25. BARONI RH
    A brief review of the VI-RADS classification for bladder tumors on MRI (and a call for increased interface, consistent communication and more joined studies by the radiological and urological communities).
    Int Braz J Urol. 2022;48:623-624.
    PubMed        


    Int J Mol Med

  26. WANG F, Liu P, An H, Zhang Y, et al
    [Corrigendum] Sulforaphane suppresses the viability and metastasis, and promotes the apoptosis of bladder cancer cells by inhibiting the expression of FAT1.
    Int J Mol Med. 2022;50.
    PubMed         Abstract available


    Int J Urol

  27. HIRATA Y, Higuchi M, Osawa T, Hinotsu S, et al
    Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.
    Int J Urol. 2022 May 21. doi: 10.1111/iju.14936.
    PubMed         Abstract available

  28. WANG Z, So WZ, Loh KY, Lim YK, et al
    Predictive biomarkers of response to bacillus Calmette-Guerin immunotherapy and bacillus Calmette-Guerin failure for non-muscle invasive bladder cancer.
    Int J Urol. 2022 May 22. doi: 10.1111/iju.14921.
    PubMed         Abstract available

  29. MIYAKE M, Kikuchi E, Shinozaki K, Piao Y, et al
    Real-world treatment patterns and clinical outcomes of Japanese patients with non-muscle invasive bladder cancer receiving intravesical bacillus Calmette-Guerin treatment.
    Int J Urol. 2022 May 21. doi: 10.1111/iju.14933.
    PubMed         Abstract available


    Int Urol Nephrol

  30. ZHUANG W, Xie H, Yu S, Li Y, et al
    Effects of treatments on gender differences in patients with localized muscle-invasive bladder cancer.
    Int Urol Nephrol. 2022 May 24. pii: 10.1007/s11255-022-03200.
    PubMed         Abstract available


    J Control Release

  31. JIAO B, Liu K, Gong H, Ding Z, et al
    Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
    J Control Release. 2022 May 23. pii: S0168-3659(22)00302.
    PubMed         Abstract available


    J Oncol

  32. QIU J, Zhang H, Xu D, Li L, et al
    Comparing Long-Term Survival Outcomes for Muscle-Invasive Bladder Cancer Patients Who Underwent with Radical Cystectomy and Bladder-Sparing Trimodality Therapy: A Multicentre Cohort Analysis.
    J Oncol. 2022;2022:7306198.
    PubMed         Abstract available


    Math Biosci Eng

  33. LIN LS, Hu SC, Lin YS, Li DC, et al
    A new approach to generating virtual samples to enhance classification accuracy with small data-a case of bladder cancer.
    Math Biosci Eng. 2022;19:6204-6233.
    PubMed         Abstract available


    Medicine (Baltimore)

  34. KAO KW, Cheng W, Chang YC
    Chondroma of the urinary bladder: A case report.
    Medicine (Baltimore). 2022;101:e29229.
    PubMed         Abstract available


    Minerva Urol Nephrol

  35. CIMADAMORE A, Teoh JY, DI Trapani E, Krajewski W, et al
    A gender-related dichotomy in bladder cancer.
    Minerva Urol Nephrol. 2022;74:376-378.
    PubMed        

  36. TARATKIN M, Morozov A, Checcucci E, Gomez Rivas J, et al
    Comment on: "Impact of the preoperative modified Glasgow Prognostic Score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder".
    Minerva Urol Nephrol. 2022;74:363-364.
    PubMed        

  37. PASTORE AL, Fuschi A, DE Nunzio C, Balzarro M, et al
    Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicenter study.
    Minerva Urol Nephrol. 2022;74:337-343.
    PubMed         Abstract available

  38. SCHUETTFORT VM, Gust K, D'Andrea D, Quhal F, et al
    Impact of the preoperative modified Glasgow Prognostic Score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder.
    Minerva Urol Nephrol. 2022;74:302-312.
    PubMed         Abstract available

  39. FICARRA V, Giannarini G, Alario G, Tulone G, et al
    Urethral fixation technique improves urinary continence recovery in men undergoing open radical cystectomy and ileal orthotopic neobladder.
    Minerva Urol Nephrol. 2022;74:313-320.
    PubMed         Abstract available

  40. DALLA VOLTA A, Petrelli F, Luciani A, Caramella I, et al
    Is adjuvant immunotherapy effective in patients with urothelial cancer?
    Minerva Urol Nephrol. 2022;74:252-254.
    PubMed        


    Neuro Endocrinol Lett

  41. ZHANG J, Li J, Zhai L, Lin L, et al
    Coexisting of myasthenia gravis and fulminant myocarditis induced by nivolumab in a patient with ureteral epithelial cancer.
    Neuro Endocrinol Lett. 2021;42:383-386.
    PubMed         Abstract available


    Prog Urol

  42. EL AZAB A, Hossam E, Abdelrahman I, Aboulkassem H, et al
    Variables affecting quality of life after Radical cystectomy and neobladder substitution: Egyptian National Cancer Institute experience.
    Prog Urol. 2022;32:410-418.
    PubMed         Abstract available

  43. DOBE TR, Belhadj Y, Michel C, Djouadou M, et al
    Perioperative results of radical cystectomy after neoadjuvant chemotherapy according to the implementation of ERAS pathway.
    Prog Urol. 2022;32:401-409.
    PubMed         Abstract available


    Scand J Urol

  44. HOLMANG S, Hedelin H
    Standardized care pathway for bladder cancer in Sweden. So far lots of pain but little gain.
    Scand J Urol. 2022 May 23:1-2. doi: 10.1080/21681805.2022.2078876.
    PubMed        


    Sci Rep

  45. TSUKAHARA S, Shiota M, Takamatsu D, Nagakawa S, et al
    Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine.
    Sci Rep. 2022;12:8535.
    PubMed         Abstract available


    Spectrochim Acta A Mol Biomol Spectrosc

  46. BAI X, Lin J, Wu X, Lin Y, et al
    Label-free detection of bladder cancer and kidney cancer plasma based on SERS and multivariate statistical algorithm.
    Spectrochim Acta A Mol Biomol Spectrosc. 2022;279:121336.
    PubMed         Abstract available


    Toxicol Pathol

  47. WAKUI S, Takahashi H, Muto T
    In Utero Exposure to 3,3',4,4', 5-Pentachlorobiphenyl Dose-Dependently Induces N-butyl-4-(hydroxybutyl) Nitrosamine in Rats With Urinary Bladder Carcinoma.
    Toxicol Pathol. 2022;50:366-380.
    PubMed         Abstract available


    Urol Oncol

  48. NGUYEN C, Ghodoussipour S, Winter M, Cacciamani G, et al
    Chronic kidney disease and radical cystectomy for bladder cancer: perioperative and oncologic outcomes in 1,214 patients.
    Urol Oncol. 2022 May 19. pii: S1078-1439(22)00121.
    PubMed         Abstract available


    Vet Med Sci

  49. VAN DER WEYDEN L, Tibbs C, Knott C, Dobromylskyj M, et al
    Metastatic urothelial carcinoma of the urinary bladder in a Sumatran tiger (Panthera tigris sondaica).
    Vet Med Sci. 2022;8:1288-1293.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: